Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AvidinOX + trastuzumab + pertuzumab
- Development stage
- Preclinical
- Lead developer
- Kiran Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
AvidinOX is a proprietary platform technology developed by Kiran Biotech, utilizing a chemically oxidized form of avidin. When injected into a target tissue, such as a tumor, AvidinOX forms covalent bonds with local proteins, creating a stable artificial receptor that persists for weeks. This platform is designed to capture and concentrate biotinylated therapeutic agents at the site of injection. In the context of HER2-positive tumors, the platform is used to deliver and localize the HER2-targeted monoclonal antibodies trastuzumab and pertuzumab. Trastuzumab binds to domain IV of the HER2 receptor, while pertuzumab binds to domain II, together providing a comprehensive blockade of HER2 signaling and dimerization. The combination aims to enhance the anti-tumor activity of these antibodies by maintaining high local concentrations within the tumor microenvironment while potentially reducing systemic exposure.
- Other names
- AvidinOXtrastuzumabpertuzumab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on AvidinOX + trastuzumab + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AvidinOX + trastuzumab + pertuzumab.